Patents Assigned to BiPAr Sciences, Inc.
-
Publication number: 20130331457Abstract: Methods of treating bladder cancer are disclosed. The methods include administering to a patient a therapeutically effective amount of a 4-iodo-3-nitrobenzamide or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 29, 2012Publication date: December 12, 2013Applicant: BIPAR SCIENCES, INC.Inventors: Ernest KUN, Jerome MENDELEYEV, Carol BASBAUM, Hassan LEMJABBAR-ALAOUI, Valeria S. OSSOVSKAYA
-
Publication number: 20130274281Abstract: Provided herein are methods, compositions and kits for the treatment of locally advanced or metastatic breast cancer or breast cancer brain metastases. The method comprises administration of 4-iodo-3-nitrobenzamide, a metabolite or salt thereof in combination with irinotecan. The method of treating locally advanced or metastatic breast cancer comprises at least one 21 day treatment cycle.Type: ApplicationFiled: July 19, 2011Publication date: October 17, 2013Applicant: BiPar Sciences, Inc.Inventor: Charles Bradley
-
Patent number: 8377985Abstract: Methods of treating bone cancer are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia) wherein R1, R2, R3, R4, and R5 are described herein, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 30, 2008Date of Patent: February 19, 2013Assignee: BiPar Sciences, Inc.Inventors: Jerome Mendeleyev, Hassan Lemjabbar-Alaoui, Valeria S. Ossovskaya
-
Publication number: 20120269861Abstract: In one aspect, the present invention provides a method of treating breast cancer that is negative for ER, PR, and HER2, comprising administering to a subject at least one iodonitrobenzamide. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one iodonitrobenzamide in combination with at least one anti-tumor agent.Type: ApplicationFiled: March 26, 2012Publication date: October 25, 2012Applicant: BiPar Sciences, Inc.Inventors: Barry M. SHERMAN, Charles BRADLEY, Valeria OSSOVSKAYA
-
Publication number: 20120238601Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.Type: ApplicationFiled: December 12, 2011Publication date: September 20, 2012Applicant: BiPar Sciences, Inc.Inventors: Jerome MOORE, Bruce KEYT, John BURNIER, Barry SHERMAN, Max TOTROV, Valeria S. OSSOVSKAYA
-
Publication number: 20120130144Abstract: In one aspect, the present invention provides a method of treating lung cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one growth factor inhibitor. In another aspect, the present invention provides a method of treating non-small cell lung cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one growth factor inhibitor.Type: ApplicationFiled: February 4, 2010Publication date: May 24, 2012Applicant: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Patent number: 8143447Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.Type: GrantFiled: September 5, 2007Date of Patent: March 27, 2012Assignee: BiPar Sciences, Inc.Inventors: Jerome Moore, Bruce Keyt, John Burnier, Barry M. Sherman, Max Totrov, Valeria S. Ossovskaya
-
INHIBITION OF FATTY ACID SYNTHESIS BY IODO-NITROBENZAMIDE COMPOUNDS AND METHODS OF TREATMENT THEREOF
Publication number: 20120004260Abstract: The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.Type: ApplicationFiled: June 27, 2011Publication date: January 5, 2012Applicant: BiPar Sciences, Inc.Inventors: Valeria Ossovskaya, Barry Sherman -
Patent number: 7994222Abstract: The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.Type: GrantFiled: September 5, 2007Date of Patent: August 9, 2011Assignee: BiPar Sciences, Inc.Inventors: Valeria S. Ossovskaya, Barry M. Sherman
-
Publication number: 20100279327Abstract: The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention also relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP.Type: ApplicationFiled: March 26, 2010Publication date: November 4, 2010Applicant: BiPar Sciences, Inc.Inventors: Valeria S. OSSOVSKAYA, Barry M. SHERMAN
-
Patent number: 7732491Abstract: In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.Type: GrantFiled: November 11, 2008Date of Patent: June 8, 2010Assignee: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Publication number: 20100009930Abstract: In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.Type: ApplicationFiled: July 14, 2009Publication date: January 14, 2010Applicant: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Publication number: 20100003192Abstract: In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.Type: ApplicationFiled: July 1, 2009Publication date: January 7, 2010Applicant: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Publication number: 20090291924Abstract: The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein; b) based on the interaction, designing a candidate tubulin inhibitor; c) determining an interaction between the tubulin protein and the candidate tubulin inhibitor by evaluating a binding of the tubulin protein to the candidate tubulin inhibitor; and d) concluding that the candidate tubulin inhibitor inhibits the tubulin protein wherein the conclusion is based on the interaction of step c). The invention also provides compositions and methods of treatment of diseases with the candidate tubulin inhibitors.Type: ApplicationFiled: May 21, 2009Publication date: November 26, 2009Applicant: BiPar Sciences, Inc.Inventors: Valeria Ossovskaya, John Burnier, Barry Sherman, Max Totrov
-
Publication number: 20090275608Abstract: Disclosed are methods of identifying a disease treatable with modulators of differentially expressed genes in a disease, including at least PARP modulators, by identifying the level of expression of differentially expressed genes, including at least PARP, in a plurality of samples from a population, making a decision regarding identifying the disease treatable by modulators to the differentially expressed genes wherein the decision is made based on the level of expression of the differentially expressed genes. The method can further comprise treating the disease in a subject population with modulators of identified differentially expressed genes. The methods relate to identifying up-regulated expression of identified differentially-expressed genes in a disease and making a decision regarding the treatment of the disease. The level of expression of the differentially expressed genes in a disease can also help in determining the efficacy of the treatment with modulators to the differentially expressed genes.Type: ApplicationFiled: February 4, 2009Publication date: November 5, 2009Applicant: BiPar Sciences, Inc.Inventors: Valeria S. Ossovskaya, Barry M. Sherman
-
Patent number: 7538252Abstract: The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein; b) based on the interaction, designing a candidate tubulin inhibitor; c) determining an interaction between the tubulin protein and the candidate tubulin inhibitor by evaluating a binding of the tubulin protein to the candidate tubulin inhibitor; and d) concluding that the candidate tubulin inhibitor inhibits the tubulin protein wherein the conclusion is based on the interaction of step c). The invention also provides compositions and methods of treatment of diseases with the candidate tubulin inhibitors.Type: GrantFiled: September 5, 2007Date of Patent: May 26, 2009Assignee: BiPar Sciences, Inc.Inventors: Valeria Ossovskaya, John Burnier, Barry Sherman, Max Totrov
-
Publication number: 20090076122Abstract: The invention relates to a method of modulating poly(ADP-ribose)polymerase-1 (PARP-1) activity in a mammal comprising administering to a mammal an effective amount of an organic aromatic compound having from 4 to about 35 carbon atoms, wherein said organic aromatic compound is capable of binding the arginine-34 moiety located in Zinc finger-1 of the PARP-1 enzyme and wherein said organic aromatic compound has electron donating capabilities such that it's ?-electron system will interact with the positively charged (cationic) guanidinium moiety of the specific arginine-34 residue of the Zinc-1 finger of PARP-1 and does not contain benzamide or lactam substituents. In particular, substituted benzopyrones and substituted indoles and their pharmaceutical compositions containing such compounds that modulate the activity of PARP-1, are described.Type: ApplicationFiled: December 2, 2008Publication date: March 19, 2009Applicant: BIPAR SCIENCES, INC.Inventors: Ernest KUN, Jerome MENDELEYEV, Pal BAUER
-
Publication number: 20080262062Abstract: The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively.Type: ApplicationFiled: November 14, 2007Publication date: October 23, 2008Applicant: BIPAR SCIENCES, INC.Inventors: Valeria S. Ossovskaya, Barry M. Sherman
-
Patent number: 7405227Abstract: Methods of treating ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eve cancer, central nervous system cancer, thyroid cancer and lung cancer are disclosed. Specifically disclosed are methods of treating ovarian adenocarcinoma that has migrated into the abdominal cavity, a transitional cell carcinoma of the bladder, an epithelioid carcinoma in a pancreatic duct, an adenocarcinoma in a pancreatic duct, an adenocarcinoma in the cervical epithelium. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia) wherein R1, R2, R3, R4, and R5 are described herein, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.Type: GrantFiled: July 18, 2006Date of Patent: July 29, 2008Assignee: BiPAr Sciences, Inc.Inventors: Ernest Kun, Jerome Mendeleyev, Carol Basbaurn, Hassan Lemjabbar-Alaoui, Valeria Ossovskaya
-
Publication number: 20080176946Abstract: The present invention provides compositions of matter, kits, and methods for use in treating cancer and viral conditions. In particular the invention provides for pharmaceutical compositions containing nitrobenzamide compounds that have enhanced solubility in aqueous solutions.Type: ApplicationFiled: January 16, 2008Publication date: July 24, 2008Applicant: BIPAR SCIENCES, INC.Inventors: Valeria s. Ossovskaya, Lingyun Li, Barry Sherman